The short answer
Being recategorized or placed under a draft enforcement-discretion policy is not the same as being FDA-approved. A change in how a rule is enforced is not a finding that a substance is safe, effective, or approved for human use.
This article explains documented U.S. federal actions and the arguments around them. It is not a guide to obtaining, importing, compounding, or using any peptide, and it does not recommend any product.
Compounded is not approved
Compounding is generally the practice of a licensed pharmacist or physician combining, mixing, or altering ingredients to create a medication tailored to an individual patient.
Under section 503A of the Federal Food, Drug, and Cosmetic Act, one condition for certain legal exemptions is that bulk ingredients match a USP or NF monograph, are components of FDA-approved drugs, or appear on a list developed through rulemaking, the 503A bulks list.
What tightened, and what later moved
FDA has placed some nominated bulk substances in “category 2” when it identified potential significant safety risks.
HHS’s later policy is explicit about what those dates did not do.
In other words, coming off the category-2 list was not the same as being added to the 503A bulks list, and it was not FDA approval.
The October 30, 2026 draft policy
On October 30, 2026, HHS published a Federal Register notice announcing a draft enforcement-discretion policy for 503A compounding using certain peptide bulk substances.
The same notice says what the draft is not.
The accompanying policy names six substances in Appendix A: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.
HHS describes its interim choice as an effort to expand access under safeguards, and to discourage widespread use of certain research-use-only peptides from foreign manufacturers.
That is a documented disagreement between offices. It is not a secret plot, and it is not proof either side has finished the scientific argument.
A draft enforcement-discretion policy is not a final rule, not an FDA finding of safety and effectiveness, and not permission to treat these substances as approved drugs.
Peptides not on that six-item list should not be swept into the same sentence. If a substance has no documented reversal or discretion policy, we will not invent one.
A separate story: shortage compounding of approved GLP-1 medicines
Approved semaglutide and tirzepatide injections are a different legal track.
Compounded copies of commercially available drugs are restricted under sections 503A and 503B.
That sequence is closer to a temporary allowance that later tightened than to an “unblocking” of unapproved research peptides. It should not be blended into the six-peptide story.
Why people want access, and why regulators worry
Consumers and some clinicians argue that approved options can be expensive or unavailable for a person’s situation, that compounding exists to tailor care, and that adults should be able to take responsibility for choices made with a licensed prescriber. That argument is about affordability, autonomy, and distrust of a system that can feel like gatekeeping.
Regulators argue from a different ledger: identity, purity, sterility, immunogenicity, impurities, and the absence of adequate human evidence.
Those are evidence-and-quality concerns. They can be discussed without accusing FDA scientists of bad faith.
Manufacturers of approved drugs have a commercial interest in defending products that went through costly trials, and they have objected to compounded copies after shortages eased. That incentive is real. High prices and limited access are also real.
Neither fact proves that a particular unapproved peptide works, or that a particular official was corrupted. Incentives explain pressure. They do not replace trial evidence.
Our publisher recalls a different experience abroad: being able to walk into a drugstore in Ecuador and buy medicines he needed, with responsibility on the user to seek direction. That is a personal recollection. It is not a description of current Ecuadorian law, not a survey of drug quality in any country, and not evidence that a looser counter is safer.
It is included because it captures a tension many readers feel, between wanting adults treated as responsible and wanting some independent check on what is in the vial.
The underground market is not a quality system
Demand does not disappear when a clinic or pharmacy cannot lawfully supply a substance.
A research-use label is not a finding that a product is suitable for people. A certificate of analysis can describe what was tested in a sample. It does not prove a product is safe or effective, or that the next vial matches the last one. We explain how to read one in How to Read a Peptide Certificate of Analysis.
Informal markets also carry risks a dissatisfied buyer has little power to unwind: the wrong identity, the wrong strength, contamination, sterility failures, counterfeit packaging, and no reliable path for a complaint. This article will not name vendors, routes, or methods.
Personal importation is similarly cautious.
This article is not a walkthrough of that process.
What to do with a policy headline
A research-use listing, a certificate of analysis, or a policy headline is not care. Ask what changed, what did not, whether it is final or draft, and whether anyone has found the product safe and effective for the use being talked about.
Bring questions about any medicine, compounded or approved, to a licensed clinician.
This article does not recommend buying, importing, compounding, preparing, or using any peptide or unapproved drug, and it gives no dosing or procurement guidance. Personal decisions belong with you and a qualified clinician.
